Copy of Moderna Vax patent application March 28, 2019

Key parts magnified United States Ciaramelia et al. US 2) Patent Application Publication Pub. No.: US Al HPIV3 RNA VACCINES (71) Applicant: ModernaTTX. Ine…

Cambridge, MA (us) (72) laventocs: Gluseppe Ciaramella, Sudbury, MA (USk: Sunay Himansu, Winchester, (73) Assignce: ModermaTTX, In.,

Cambridge, MA (us) (21) Appl. No (22) Viled 28, 2019 Related U.S. Application Duta Continuation of application No, 16’040,981, filed on 2018, No. 10,272,150, which is No. filed on 10,054,934, which is ‘of application No. PCTIUS2016: 058327, filed on Oct, 21, 2016 Provisional 2015, application provisional. No.

No. filed oa Oct. 2015, provisional application No. 6 Ged on Oxt. 28, 2015, provisional applicat filed on Oct. 28, 2015, provisional ap- plication No. filed on Oct. 28, 2015, (43) Pub, Date: Aug. 8, 2019 provisional application No, filed Oxt. application No 2015, provisional application No. 2, 2015, provi sional application No 015, provisional ap- 837, filed on Oct. 22, 2015, No, filed on No. Publication Classification (1) Iat. Ch. A6IK (2006.01 (2006 01 A6IK (2006.01 (52) US.CL 70 (2013.01): (2013.01) ABSTRACT The disclosure relates to respiratory vinus ribanucleis acid (RNA) vascines and combs well as meth- of using the vaccine compeising, the Speeiticat includes Sequence Listing.

File (hide): (1.14 MB, 1469×666, ClipboardImage.png) (h) (u) US 20190240317 Al person who fell ill during a 2012 outbreak of a new flu. As of July 2015, MERS-CoV cases have been reported in over 21 countries. The outbreaks of MERS-CoV have mised serious concerns world-wide, reinforcing the importance of developing effective and safe vaccine candidates against MERS-CoV. [0011] Severe acute respiratory syndrome (SARS) emerged in China in 2002 and spread to other countries before brought under control.

Because of concern for reemergence or a deliberate release of the SARS coronavi- mus, vaccine development was initiated. [0012] Deoxyribonucleic acid (DNA) vaccination is one technique used to stimulate humoral and cellular immune responses to foreign antigens, such as hMPV antigens PIV antigens RSV antigens.

The direct injection of Aug. 8, 2019 co-opt natural cellular machinery. Unlike traditional vac- cines, which are manufactured ex vivo and may trigger unwanted cellular responses, RNA (e.g., mRNA) vaccines are presented to the cellular system in a more native fashion. [0015] In some aspects the invention is a respiratory virus vaccine, comprising at least one RNA polynucleotide having an open reading frame encoding at least one respiratory virus antigenic polypeptide, formulated in a cationic lipid nanoparticle. [0016]

Surprisingly, in some ts-it has also been shown that efficacy of mRNA vaccines can be significantly enhanced when combined with a flagellin adjuvant, in particular, when one or more antigen-encoding mRNAs is combined with an mRNA encoding flagellin.

Moderna patent application March 28 2019 On March 28, 2019, Moderna, the poster child of the mRNA supposed vaccine, lodged an amendment to a previously multi-rejected patent. Included in that amendment were the following words: “Because of a concern for re-emergence or a deliberate release of the SARS coronavirus, vaccine development was initiated.” – iFunny key part magnified I obtained this information from this felloe United States Ciaramelia et al. US 2) Patent Application Publication Pub. No.: US Al HPIV3 RNA VACCINES (71) Applicant: ModernaTTX. Ine…

Cambridge, MA (us) (72) laventocs: Gluseppe Ciaramella, Sudbury, MA (USk: Sunay Himansu, Winchester, (73) Assignce: ModermaTTX, In., Cambridge, MA (us) (21) Appl. No (22) Viled 28, 2019 Related U.S. Application Duta Continuation of application No, 16’040,981, filed on 2018, No. 10,272,150, which is No. filed on 10,054,934, which is ‘of application No. PCTIUS2016: 058327, filed on Oct, 21, 2016 Provisional 2015, application provisional.

No. No. filed oa Oct. 2015, provisional application No. 6 Ged on Oxt. 28, 2015, provisional applicat filed on Oct. 28, 2015, provisional ap- plication No. filed on Oct. 28, 2015, (43) Pub, Date: Aug. 8, 2019 provisional application No, filed Oxt. application No 2015, provisional application No. 2, 2015, provi sional application No 015, provisional ap- 837, filed on Oct. 22, 2015, No, filed on No.

Publication Classification (1) Iat. Ch. A6IK (2006.01 (2006 01 A6IK (2006.01 (52) US.CL 70 (2013.01): (2013.01) ABSTRACT The disclosure relates to respiratory vinus ribanucleis acid (RNA) vascines and combs well as meth- of using the vaccine compeising, the Speeiticat includes Sequence Listing.

File (hide): (1.14 MB, 1469×666, ClipboardImage.png) (h) (u) US 20190240317 Al person who fell ill during a 2012 outbreak of a new flu. As of July 2015, MERS-CoV cases have been reported in over 21 countries.

The outbreaks of MERS-CoV have mised serious concerns world-wide, reinforcing the importance of developing effective and safe vaccine candidates against MERS-CoV. [0011] Severe acute respiratory syndrome (SARS) emerged in China in 2002 and spread to other countries before brought under control.

Because of concern for reemergence or a deliberate release of the SARS coronavi- mus, vaccine development was initiated. [0012] Deoxyribonucleic acid (DNA) vaccination is one technique used to stimulate humoral and cellular immune responses to foreign antigens, such as hMPV antigens PIV antigens RSV antigens. The direct injection of Aug. 8, 2019 co-opt natural cellular machinery.

Unlike traditional vac- cines, which are manufactured ex vivo and may trigger unwanted cellular responses, RNA (e.g., mRNA) vaccines are presented to the cellular system in a more native fashion. [0015] In some aspects the invention is a respiratory virus vaccine, comprising at least one RNA polynucleotide having an open reading frame encoding at least one respiratory virus antigenic polypeptide, formulated in a cationic lipid nanoparticle. [0016]

Surprisingly, in some ts-it has also been shown that efficacy of mRNA vaccines can be significantly enhanced when combined with a flagellin adjuvant, in particular, when one or more antigen-encoding mRNAs is combined with an mRNA encoding flagellin.

Moderna patent application March 28 2019 On March 28, 2019, Moderna, the poster child of the mRNA supposed vaccine, lodged an amendment to a previously multi-rejected patent. Included in that amendment were the following words: “Because of a concern for re-emergence or a deliberate release of the SARS coronavirus, vaccine development was initiated.”